128 related articles for article (PubMed ID: 38454021)
1. MYC activity at enhancers drives prognostic transcriptional programs through an epigenetic switch.
Jakobsen ST; Jensen RAM; Madsen MS; Ravnsborg T; Vaagenso CS; Siersbæk MS; Einarsson H; Andersson R; Jensen ON; Siersbæk R
Nat Genet; 2024 Apr; 56(4):663-674. PubMed ID: 38454021
[TBL] [Abstract][Full Text] [Related]
2. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
3. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
[TBL] [Abstract][Full Text] [Related]
4. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
5. Integrative analysis of RNA polymerase II and transcriptional dynamics upon MYC activation.
de Pretis S; Kress TR; Morelli MJ; Sabò A; Locarno C; Verrecchia A; Doni M; Campaner S; Amati B; Pelizzola M
Genome Res; 2017 Oct; 27(10):1658-1664. PubMed ID: 28904013
[TBL] [Abstract][Full Text] [Related]
6. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.
Gryder BE; Yohe ME; Chou HC; Zhang X; Marques J; Wachtel M; Schaefer B; Sen N; Song Y; Gualtieri A; Pomella S; Rota R; Cleveland A; Wen X; Sindiri S; Wei JS; Barr FG; Das S; Andresson T; Guha R; Lal-Nag M; Ferrer M; Shern JF; Zhao K; Thomas CJ; Khan J
Cancer Discov; 2017 Aug; 7(8):884-899. PubMed ID: 28446439
[TBL] [Abstract][Full Text] [Related]
7. Enhancers are activated by p300/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release.
Narita T; Ito S; Higashijima Y; Chu WK; Neumann K; Walter J; Satpathy S; Liebner T; Hamilton WB; Maskey E; Prus G; Shibata M; Iesmantavicius V; Brickman JM; Anastassiadis K; Koseki H; Choudhary C
Mol Cell; 2021 May; 81(10):2166-2182.e6. PubMed ID: 33765415
[TBL] [Abstract][Full Text] [Related]
8. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation.
Shi J; Whyte WA; Zepeda-Mendoza CJ; Milazzo JP; Shen C; Roe JS; Minder JL; Mercan F; Wang E; Eckersley-Maslin MA; Campbell AE; Kawaoka S; Shareef S; Zhu Z; Kendall J; Muhar M; Haslinger C; Yu M; Roeder RG; Wigler MH; Blobel GA; Zuber J; Spector DL; Young RA; Vakoc CR
Genes Dev; 2013 Dec; 27(24):2648-62. PubMed ID: 24285714
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer-Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression.
Chen Y; Ying Y; Ma W; Ma H; Shi L; Gao X; Jia M; Li M; Song X; Kong W; Chen W; Zheng X; Muluh TA; Wang X; Wang M; Shu XS
Cancer Res; 2024 Apr; 84(8):1237-1251. PubMed ID: 38241700
[TBL] [Abstract][Full Text] [Related]
10. Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release.
Liu W; Ma Q; Wong K; Li W; Ohgi K; Zhang J; Aggarwal A; Rosenfeld MG
Cell; 2013 Dec; 155(7):1581-1595. PubMed ID: 24360279
[TBL] [Abstract][Full Text] [Related]
11. c-Myc represses the proximal promoters of GADD45a and GADD153 by a post-RNA polymerase II recruitment mechanism.
Barsyte-Lovejoy D; Mao DY; Penn LZ
Oncogene; 2004 Apr; 23(19):3481-6. PubMed ID: 15021909
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin-Dependent Turnover of MYC Antagonizes MYC/PAF1C Complex Accumulation to Drive Transcriptional Elongation.
Jaenicke LA; von Eyss B; Carstensen A; Wolf E; Xu W; Greifenberg AK; Geyer M; Eilers M; Popov N
Mol Cell; 2016 Jan; 61(1):54-67. PubMed ID: 26687678
[TBL] [Abstract][Full Text] [Related]
13. Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma.
Agnarelli A; Mitchell S; Caalim G; Wood CD; Milton-Harris L; Chevassut T; West MJ; Mancini EJ
Hematol Oncol; 2022 Aug; 40(3):417-429. PubMed ID: 35544413
[TBL] [Abstract][Full Text] [Related]
14. BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC.
Ba M; Long H; Yan Z; Wang S; Wu Y; Tu Y; Gong Y; Cui S
J Cell Biochem; 2018 Jan; 119(1):973-982. PubMed ID: 28681984
[TBL] [Abstract][Full Text] [Related]
15. Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia.
Yashiro-Ohtani Y; Wang H; Zang C; Arnett KL; Bailis W; Ho Y; Knoechel B; Lanauze C; Louis L; Forsyth KS; Chen S; Chung Y; Schug J; Blobel GA; Liebhaber SA; Bernstein BE; Blacklow SC; Liu XS; Aster JC; Pear WS
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):E4946-53. PubMed ID: 25369933
[TBL] [Abstract][Full Text] [Related]
16. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
[TBL] [Abstract][Full Text] [Related]
17. Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells.
Zhang W; Prakash C; Sum C; Gong Y; Li Y; Kwok JJ; Thiessen N; Pettersson S; Jones SJ; Knapp S; Yang H; Chin KC
J Biol Chem; 2012 Dec; 287(51):43137-55. PubMed ID: 23086925
[TBL] [Abstract][Full Text] [Related]
18. miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.
Gen Y; Muramatsu T; Inoue J; Inazawa J
Cancer Res; 2021 Oct; 81(20):5190-5201. PubMed ID: 34353856
[TBL] [Abstract][Full Text] [Related]
19. Hold the MYCrophone: MYC Invades Enhancers to Control Cancer Type Gene Programs.
MacPherson-Hawthorne KA; Sears RC
Cancer Res; 2024 May; ():. PubMed ID: 38695859
[TBL] [Abstract][Full Text] [Related]
20. The PVT1 lncRNA is a novel epigenetic enhancer of MYC, and a promising risk-stratification biomarker in colorectal cancer.
Shigeyasu K; Toden S; Ozawa T; Matsuyama T; Nagasaka T; Ishikawa T; Sahoo D; Ghosh P; Uetake H; Fujiwara T; Goel A
Mol Cancer; 2020 Nov; 19(1):155. PubMed ID: 33148262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
